Tisdag 20 Januari | 18:29:05 Europe / Stockholm
Svenska | English

Lumito

Bifogade filer

Changes to the Nomination Committee ahead of Lumito’s Annual General Meeting 2026
2026-01-20 16:30:00

Lumito AB (publ) (“Lumito” or the “Company”) today announces that the composition of the Nomination Committee ahead of the Annual General Meeting 2026 has changed as a result of changes in the Company’s ownership structure.

The composition of the Nomination Committee ahead of the Annual General Meeting 2026, based on ownership statistics from Euroclear Sweden AB as of the last banking day of September 2025, was announced by press release on 5 December 2025. As a result of subsequent changes in ownership, the composition of the Nomination Committee has changed, with Jan Östlund (representing his own shareholding) stepping down from the Nomination Committee and Mikael Gustavsson (representing Tuvedalen Limited) joining as a new member of the Nomination Committee.

Following this change, the Nomination Committee ahead of the Annual General Meeting 2026 consists of the following members:

  • Mattias Pettersson, representing his own shareholding
  • Martin Wulf, representing DMC Byggnadsaktiebolag and Kent Danneteg
  • Mikael Gustavsson, representing Tuvedalen Limited

The Annual General Meeting of Lumito will be held on 7 May 2026 at Lumito’s offices, Scheelevägen 19, Lund.

For further information, please contact:

Sanna Wallenborg, CEO Lumito
E-mail: sw@lumito.se
Ph: +4670-870 01 68

About Lumito
Lumito specialises in medical technology and translational research in digital tissue imaging. Lumito offers a groundbreaking, highly sensitive imaging technique to locate and measure protein biomarkers in tissue samples using up-converting nanoparticles (UCNPs) through its patented research platform. The technology combines image data with precise biomarker detection, enabling images with higher contrast where irrelevant background information is filtered out. The technique can enhance the analysis of tissue samples by increasing objectivity, thereby contributing to research for more quantifiable diagnoses and optimised treatments. Lumito primarily focuses on drug development and digital pathology and is a spin-off from a research group at Lund University's Department of Atomic Physics and Laser Center. www.lumito.se/en/

The share is traded on NGM Nordic SME under the name LUMITO, and Mentor is Mangold Fondkommission.

Attachments
Changes to the Nomination Committee ahead of Lumito’s Annual General Meeting 2026

Källa MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden